Precision BioSciences (DTIL) Scheduled to Post Quarterly Earnings on Thursday

Precision BioSciences (NASDAQ:DTIL) is set to announce its earnings results on Thursday, March 7th.

Precision BioSciences Stock Up 2.4 %

Shares of DTIL traded up $0.29 during trading hours on Wednesday, reaching $12.50. 84,572 shares of the company traded hands, compared to its average volume of 130,501. The stock has a market capitalization of $50.75 million, a P/E ratio of -0.64 and a beta of 1.56. Precision BioSciences has a 12-month low of $8.25 and a 12-month high of $35.70. The business has a fifty day moving average price of $12.20 and a 200-day moving average price of $11.79.

Insider Transactions at Precision BioSciences

In related news, CEO Michael Amoroso sold 4,579 shares of the company’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $10.80, for a total transaction of $49,453.20. Following the completion of the transaction, the chief executive officer now owns 11,881 shares in the company, valued at approximately $128,314.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 6,005 shares of company stock valued at $64,854 in the last ninety days. 5.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Precision BioSciences

A number of hedge funds and other institutional investors have recently made changes to their positions in DTIL. Renaissance Technologies LLC boosted its position in Precision BioSciences by 139.6% in the 3rd quarter. Renaissance Technologies LLC now owns 2,172,666 shares of the company’s stock valued at $2,824,000 after buying an additional 1,265,877 shares during the period. Millennium Management LLC raised its holdings in shares of Precision BioSciences by 269.9% in the 2nd quarter. Millennium Management LLC now owns 1,534,226 shares of the company’s stock valued at $2,455,000 after purchasing an additional 1,119,435 shares in the last quarter. Stifel Financial Corp raised its holdings in shares of Precision BioSciences by 115.5% in the 2nd quarter. Stifel Financial Corp now owns 1,958,872 shares of the company’s stock valued at $1,030,000 after purchasing an additional 1,049,771 shares in the last quarter. Citadel Advisors LLC raised its holdings in shares of Precision BioSciences by 259.4% in the 2nd quarter. Citadel Advisors LLC now owns 1,421,485 shares of the company’s stock valued at $2,274,000 after purchasing an additional 1,025,936 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its holdings in shares of Precision BioSciences by 82.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,424,535 shares of the company’s stock valued at $486,000 after purchasing an additional 643,839 shares in the last quarter. Institutional investors and hedge funds own 37.99% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating on shares of Precision BioSciences in a report on Wednesday, February 14th.

About Precision BioSciences

Precision BioSciences, Inc, a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.